Autolus Therapeutics to Report Third Quarter 2022 Financial Results on November 3, 2022
Autolus Therapeutics (Nasdaq: AUTL) will announce its Q3 2022 financial results and operational highlights on November 3, 2022, prior to the U.S. market opening. Management will hold a conference call at 8:30 am ET to discuss these results and provide updates on the company’s business. Participants are encouraged to pre-register for access details. Autolus is focused on developing next-generation programmed T cell therapies for cancer treatment, utilizing proprietary technologies for targeting and eliminating cancer cells in hematological malignancies and solid tumors.
- Focus on next-generation programmed T cell therapies for cancer treatment.
- Engagement with stakeholders through a conference call to discuss financial results.
- None.
LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, November 3, 2022.
Management will host a conference call and webcast at 8:30 am ET/1:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this link to receive the dial-in numbers and a personal PIN, which are required to access the conference call.
A simultaneous audio webcast and replay will be accessible on the events section of Autolus’ website.
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programing technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com
Contact:
Olivia Manser
+44 (0) 7780 471568
o.manser@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com
FAQ
When will Autolus Therapeutics release its Q3 2022 financial results?
What time is the Autolus Therapeutics conference call?
How can I participate in the Autolus Therapeutics conference call?
What is the focus area of Autolus Therapeutics?
